Article Figures & Data
Figures
- FIGURE 1.
Impact on management after PET for chemotherapy monitoring stratified by post-PET prognosis. Data are shown for patients undergoing PET for chemotherapy monitoring in NOPR 2006 (n = 10,234) or NOPR 2009 (n = 15,609) for any cancer type. Intended plans for other imaging or biopsy, which accounted for about 5% of cases, were excluded for clarity.
Tables
Restaging or suspected recurrence Age < 65 y Age > 65 y Chemotherapy monitoring, all ages NOPR interval cohort 2006* 2009* 2006 2009 2006 2009 Patients (n) 3,051 5,916 26,551 46,682 10,234 15,611 Age (y) Mean 53.7 55.0 74.9 75.1 72.3 72.2 25%–75% range 49–61 51–62 70–79 70–80 68–78 68–78 Eastern Cooperative Oncology Group Performance Status Asymptomatic; performance status = 0 (%) 986 (32.3) 2,107 (35.6) 10,433 (39.3) 18,290 (39.2) 2,197 (21.5) 2,929 (18.8) Symptomatic, fully ambulatory; performance status = 1 (%) 1,601 (52.5) 3,108 (52.5) 12,835 (48.3) 23,213 (49.7) 6,226 (60.8) 9,996 (64.0) Performance status = 2, 3, or 4 (%) 464 (15.2) 701 (11.8) 3,283 (12.4) 5,179 (11.1) 1,811 (17.7) 2,686 (17.2) Summary stage† No or low probability of disease recurrence 1,568 (51.4) 3,190 (53.9) 12,283 (46.3) 21,834 (46.8) 1,514 (14.8) 2,179 (14.0) Local or nodal recurrence 392 (12.8) 651 (11.0) 3,546 (13.4) 5,793 (12.4) 1,332 (13.0) 1,736 (11.1) Metastatic disease 1,091 (35.8) 2,075 (35.1) 10,721 (40.4) 19,055 (40.8) 6,431 (62.8) 10,323 (66.1) Stage unknown – – – – 957 (9.4) 1,373 (8.8) Time period Age (y) Patients (n) Nontreatment to treatment (%) Treatment to nontreatment (%) Change in management (%) 95% confidence interval Imaging-adjusted impact (%)* 95% confidence interval 2006 <65 3,051 25.7 8.0 33.7 32.0–35.4 15.2 14.0–16.5 ≥65 27,860 27.7 8.1 35.8 35.3–36.4 15.1 14.7–15.6 All ages 30,911 27.5 8.1 35.6 35.1–36.2 15.1 14.7–15.5 2009 <65 5,916 27.5 5.9 33.4 32.2–34.7 12.1 11.2–12.9 ≥65 48,831 29.9 6.0 35.9 35.4–36.3 12.6 12.3–12.9 All ages 54,747 29.6 6.0 35.6 35.2–36.0 12.6 12.3–12.8 ↵* Imaging-adjusted impact: No benefit from PET was assumed for cases with a plan before PET of alternative imaging.
- TABLE 3
Impact of PET on Intended Management for Restaging in Patients Older Than 65 Years
Cancer Time period Patients (n) Nontreatment to treatment (%) Treatment to nontreatment (%) Change in management (%) 95% confidence interval Imaging-adjusted impact (%)* 95% confidence interval Bladder 2006 3,322 28.2 7.9 36.1 34.5–37.8 16.0 14.8–17.3 2009 5,539 29.4 5.9 35.3 34.0–36.6 12.8 11.9–13.7 Kidney 2006 3,068 24.8 7.3 32.1 30.5–33.8 14.4 13.2–15.7 2009 4,708 27.2 5.8 33.0 31.6–34.4 12.7 11.7–13.6 Pancreas 2006 2,876 31.6 8.6 40.2 38.4–42.0 16.5 15.1–17.9 2009 4,238 34.2 5.8 40.0 38.6–41.5 12.9 11.9–13.9 Prostate 2006 4,856 27.7 10.2 37.8 36.5–39.2 16.0 15.0–17.0 2009 5,465 34.4 7.0 41.4 40.0–42.7 13.4 12.5–14.3 Small cell lung 2006 2,810 33.0 7.8 40.7 38.9–42.6 15.2 13.9–16.5 2009 5,403 34.4 5.8 40.2 38.9–41.5 12.7 11.8–13.6 Stomach 2006 2,281 23.1 8.1 31.2 29.3–33.1 12.9 11.5–14.3 2009 3,162 26.0 6.4 32.4 30.8–34.0 11.9 10.8–13.0 Uterus 2006 3,367 26.4 7.5 33.8 32.2–35.5 14.8 13.6–16.0 2009 4,850 29.2 5.5 34.7 33.3–36.0 12.5 11.6–13.5 All other cancers 2006 5,280 27.2 7.0 34.3 33.0–35.6 14.6 13.7–15.6 2009 15,466 27.6 5.8 33.4 32.7–34.2 12.4 11.9–12.9 Total 2006 27,860 27.7 8.1 35.8 35.3–36.4 15.1 14.7–15.6 2009 48,831 29.9 6.0 35.9 35.4–36.3 12.6 12.3–12.9 ↵* Imaging-adjusted impact: No benefit from PET was assumed for cases with a plan before PET of alternative imaging.
Continue therapy Switch therapy Adjust therapy Image Stop therapy Cancer Time period Patients (n) n % n % n % n % n % Bladder 2006 1,089 283 26.0 310 28.5 156 14.3 72 6.6 268 24.6 2009 1,479 635 42.9 399 27.0 86 5.8 67 4.5 292 19.7 Kidney 2006 1,075 420 39.1 257 23.9 168 15.6 57 5.3 173 16.1 2009 1,934 1,015 52.5 478 24.7 106 5.5 92 4.8 243 12.6 Pancreas 2006 1,783 720 40.4 478 26.8 271 15.2 81 4.5 233 13.1 2009 2,198 1,103 50.2 550 25.0 151 6.9 98 4.5 296 13.5 Prostate 2006 1,024 348 34.0 261 25.5 145 14.2 69 6.7 201 19.6 2009 1,336 552 41.3 402 30.1 104 7.8 89 6.7 189 14.1 Small cell lung 2006 1,348 415 30.8 389 28.9 207 15.4 60 4.5 277 20.5 2009 2,083 1,009 48.4 503 24.1 101 4.8 74 3.6 396 19.0 Uterus 2006 818 247 30.2 260 31.8 101 12.3 48 5.9 162 19.8 2009 1,113 455 40.9 313 28.1 71 6.4 45 4.1 228 20.5 All other cancer 2006 2,100 760 36.2 538 25.6 290 13.8 110 5.2 402 19.1 2009 4,387 2,047 46.7 1,121 25.6 284 6.5 198 4.5 737 16.8 Total cases 2006 10,234 3,554 34.7 2,735 26.7 1,492 14.6 552 5.4 1,901 18.6 2009 15,611 7,315 46.9 4,049 25.9 976 6.3 722 4.6 2,547 16.3
Jump to section
Related Articles
Cited By...
- The Future of Nuclear Medicine as an Independent Specialty
- Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities--Phase III Studies
- Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry
- 18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry
- Follow-up or Surveillance 18F-FDG PET/CT and Survival Outcome in Lung Cancer Patients
- Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry
- Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
- Intended Versus Inferred Care After PET Performed for Initial Staging in the National Oncologic PET Registry
- A Broader Importance of NOPR to the Future of Nuclear Imaging